{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-126873","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.936559+00:00","generated_at":"2026-06-07T11:19:27.261360+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Rhythm Pharmaceuticals amends bylaws to address universal proxy rules and enhance stockholder proposal disclosures","bullets":["Amended and restated bylaws adopted by Board on Dec 14, 2023, effective same day.","Clarifies compliance with SEC Rule 14a-19 for proxy solicitations supporting director nominees.","Enhances disclosure requirements for stockholder nominations and other business proposals.","Requires any stockholder soliciting proxies to use a proxy card color other than white.","Deleted obsolete provisions and made technical, clarifying changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-126873","json":"https://secwatch.observer/filing/0001104659-23-126873.json","markdown":"https://secwatch.observer/filing/0001104659-23-126873.md","text":"https://secwatch.observer/filing/0001104659-23-126873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923126873/0001104659-23-126873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923126873/tm2332524d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:19:27.261360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"956ecad9d1ff264a313409d9c559bba9d3a27d37","claim":"RHYTHM PHARMACEUTICALS, INC.: Amended and restated bylaws to adopt universal proxy rules, streamline stockholder nomination procedures, require white proxy card for soliciting stockholders, and delete obsolete provisions (effective 2023-12-14).","evidence_excerpt":"On December 14, 2023, the Board of Directors (the “ Board ”) of Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923126873/0001104659-23-126873-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}